Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2

dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorShu, C. A.
dc.contributor.authorGoto, K.
dc.contributor.authorOhe, Y.
dc.contributor.authorBesse, B.
dc.contributor.authorPark, K.
dc.contributor.authorWang, Y.
dc.contributor.authorGriesinger, F.
dc.contributor.authorYang, J. C-H.
dc.contributor.authorFelip, E.
dc.contributor.authorSanborn, R. E.
dc.contributor.authorCaro, R. Bernabe
dc.contributor.authorBauml, J. M.
dc.contributor.authorChen, J.
dc.contributor.authorFennema, E.
dc.contributor.authorMahoney, J.
dc.contributor.authorTrani, L.
dc.contributor.authorKnoblauch, R. E.
dc.contributor.authorThayu, M.
dc.contributor.authorCho, B. C.
dc.contributor.authoraffiliation[Shu, C. A.] Columbia Univ, Med Ctr, Med, New York, NY USA
dc.contributor.authoraffiliation[Goto, K.] Natl Canc Ctr Hosp East, Thorac Oncol, Kashiwa, Chiba, Japan
dc.contributor.authoraffiliation[Ohe, Y.] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
dc.contributor.authoraffiliation[Besse, B.] Gustave Roussy, Canc Med, Villejuif, France
dc.contributor.authoraffiliation[Park, K.] Sungkyunkwan Univ, Samsung Med Ctr, Med, Sch Med, Seoul, South Korea
dc.contributor.authoraffiliation[Wang, Y.] Sichuan Univ, West China Hosp, Inst Drug Clin Trial, Chengdu, Peoples R China
dc.contributor.authoraffiliation[Wang, Y.] Sichuan Univ, West China Hosp, Dept Thorac Canc, Chengdu, Peoples R China
dc.contributor.authoraffiliation[Wang, Y.] Collaborat Innovat Ctr, Chengdu, Peoples R China
dc.contributor.authoraffiliation[Griesinger, F.] Carl von Ossietzky Univ Oldenburg, Hematol & Oncol, Pius Hosp, Oldenburg, Germany
dc.contributor.authoraffiliation[Yang, J. C-H.] Natl Taiwan Univ, Med Oncol, Ctr Canc, Taipei, Taiwan
dc.contributor.authoraffiliation[Felip, E.] Vall Hebron Univ Hosp, Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Sanborn, R. E.] Earle Chiles Res Inst, Providence Canc Inst, Med Oncol, Portland, OR USA
dc.contributor.authoraffiliation[Caro, R. Bernabe] Hosp Univ Virgen Rocio, Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Bauml, J. M.] Univ Penn, Perelman Sch Med, Med, Philadelphia, PA USA
dc.contributor.authoraffiliation[Chen, J.] Janssen R&D, Clin Biostat, Spring House, PA USA
dc.contributor.authoraffiliation[Fennema, E.] Janssen R&D, Oncol, Spring House, PA USA
dc.contributor.authoraffiliation[Trani, L.] Janssen R&D, Oncol, Spring House, PA USA
dc.contributor.authoraffiliation[Knoblauch, R. E.] Janssen R&D, Oncol, Spring House, PA USA
dc.contributor.authoraffiliation[Thayu, M.] Janssen R&D, Oncol, Spring House, PA USA
dc.contributor.authoraffiliation[Mahoney, J.] Janssen R&D, Clin Oncol, Spring House, PA USA
dc.contributor.authoraffiliation[Cho, B. C.] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Med Oncol, Seoul, South Korea
dc.contributor.funderJanssen
dc.date.accessioned2025-01-07T15:32:57Z
dc.date.available2025-01-07T15:32:57Z
dc.date.issued2021-09-21
dc.identifier.doi10.1016/j.annonc.2021.08.1798
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.1798
dc.identifier.urihttps://hdl.handle.net/10668/27229
dc.identifier.wosID700527702212
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS952-S953
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleAmivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files